Cellectar Biosciences Inc (CLRB) FinancialsCLRBCellectar Biosciences Inc

Evaluating the bottom line, Cellectar Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -125.99%, provide a clear picture of how effectively CLRB converts its operational activities into shareholder value.

In the context of the broader market, CLRB competes directly with industry leaders such as LSTA and GTBP. With a market capitalization of $12.00M, it holds a leading position in the sector. When comparing efficiency, CLRB's gross margin of N/A stands against LSTA's N/A and GTBP's N/A. Such benchmarking helps identify whether Cellectar Biosciences Inc is trading at a premium or discount relative to its financial performance.

The company has been experiencing losses, with a net income of -$6.9 million in Q2 2026 and a negative EPS of -0.57. However, it has a current ratio of 6.66, indicating strong liquidity.